Home » Topics » Disease categories and therapies » Nephrology

Nephrology
RSS

New muscarinic antagonists developed at Roche

Oct. 4, 1999

Alpha1A/1L-adrenoceptor agonists disclosed for urinary incontinence, etc.

Oct. 1, 1999

Preclinical study results support potential of NK1 antagonist in treating micturition disorders

Sep. 23, 1999

Ortho-McNeil designs new prostate-selective alpha1a-adrenoceptor antagonists

Sep. 15, 1999

Synaptic and Merck & Co. discontinue development of oral treatment for BPH

Sep. 13, 1999

Wider therapeutic index predicted for Ditropan XL compared to conventional Ditropan

Sep. 10, 1999

NexMed reports progress with topical treatments for sexual dysfunction

Sep. 9, 1999

FibroGen and Taisho to collaborate on kidney fibrosis research

Sep. 8, 1999

YM-31758: a potent and selective inhibitor of human prostatic 5alpha-reductase

Sep. 6, 1999

New treatment for urinary incontinence in the Recordati pipeline

Aug. 31, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 15, 2026.
Microbiota modulates the antidepressant effects of GLP-1 analogues
BioWorld Science
Liraglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist used in diabetes and obesity, could alleviate depression through a pathway that does not depend on...
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
EHA 2026: With new lenses, a changing view on pediatric cancers
BioWorld
In the most simplistic view, adult cancers occur because “immature cells are exposed to mutagens, accumulate mutations, and across life ultimately transform into...
Enliven’s phase I CML data Enable phase III with BCR/ABL1 bid
BioWorld
Tolerability is a key factor in the appeal of Enliven Therapeutics Inc.’s ELVN-001 for previously treated chronic myeloid leukemia (CML), which yielded positive...